4.7 Article

Do Regulatory Changes Seriously Affect the Medical Devices Industry? Evidence From the Czech Republic

期刊

FRONTIERS IN PUBLIC HEALTH
卷 9, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fpubh.2021.666453

关键词

risk; patient safety; regulation; innovation; SME; medical devices

资金

  1. project (GACR) Investment evaluation of medical device development run at the Faculty of Informatics and Management of the University of Hradec Kralove, Czech Republic [17-03037S]

向作者/读者索取更多资源

The paper examines the challenges and risks faced by the European medical devices industry, particularly focusing on SMEs in the Czech Republic. Findings indicate that the new legislation will improve safety but may come with higher costs and administrative burdens, potentially forcing some SMEs to diversify away from medical products.
Background: Within the EU, some of the challenges and perceived risks now facing medical device (MD) developers result from changes in the regulatory framework, emphasizing safety. Therefore, medical technology companies must adopt stricter quality assurance measures so that individual devices can be speedily tracked and retrieved in emergency situations. Objectives: We highlight the challenges and risks faced by the European medical devices industry, particularly those faced by SMEs in the Czech Republic. We address two important research questions: Q1. Do advantages from increased regulation outweigh the additional expenses? Q2. As many MD developers are SMEs, will the new regulatory regime result in some of those companies going out of business and therefore impede future innovation? Methods: The paper focuses on a single case study, with the situation and outcomes discussed in the context of the financial results of a further 50 medical device manufacturers marketing in the Czech Republic. Results: Our findings suggest that the new legislation will result in improved safety, facilitate product recalls, but the cost and administrative burden may be high. The evidence also indicates that some SMEs may be forced to diversify to non-medical products, with the inevitable loss of innovative MDs being made available to patients and healthcare providers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据